Kornimate/medical-research-clean huggingface dataset:
a real-world research on the prevention and treatment of peritoneal metastasis and malignant ascites by intraperitoneal infusion of rmhtnf in gastric and colorectal malignant tumors

Conditions: Gastric Cancer

Summary: peritoneal metastasis is the main factor leading to poor prognosis in patients with gastric cancer or colorectal cancer. although current systemic treatment regimens can prolong the time to peritoneal metastasis, the long-term survival rate is still poor. this is mainly due to the presence of the peritoneal plasma barrier, which limits the penetration of anti-tumor drugs and thus restricts the efficacy. in contrast, the use of intraperitoneal infusion chemotherapy allows anti-tumor drugs to directly reach the abdominal cavity, exposing metastatic nodules to high concentrations of drugs, and has a significant therapeutic effect on peritoneal metastases, resulting in better therapeutic effects tumor necrosis factor (tnf) is a small molecule protein secreted by macrophages. there are two types of tnf - α: α and ß. tnf - α is produced by activated monocytes and macrophages, also known as cachectin. tnf - α is produced by activated lymphocytes, also known as lymphotoxins, and the two have similar activity. previous studies have shown that rmhtnf is safe for intraoperative perfusion in gastrointestinal tumors. in this real-world study, we will observe the safety and effectiveness of rmhtnf intraperitoneal perfusion in actual clinical settings.


Eligibility criteria:
inclusion criteria: * 1. the initial pathological diagnosis is gastric adenocarcinoma and colorectal adenocarcinoma, with clinical stage progression or advanced stage (cii-iv stage). 2. patients with recurrent/metastatic gastric adenocarcinoma and colorectal cancer. 3. age range from 18 to 80 years old; 4. male or non pregnant or lactating female; 5. the bone marrow reserve function is good, and the blood routine meets the following conditions: white blood cell count ≥ 3.5 × 109/l, neutrophils ≥ 1.5 × 109/l, platelet count ≥ 100 × 109/l, hemoglobin ≥ 90 g/l; 6. the organ function is good, and the biochemical examination meets the following conditions: alt ≤ 2.5 x upper limit of normal (uln), ast ≤ 2.5 x uln, serum total bilirubin ≤ 1.5 x uln, and blood creatinine ≤ 1.5 x uln; 7. functional status: 0-1 (ecog); 8. preoperative asa grading i-iii; 9. informed consent form has been signed for clinical treatment. exclusion criteria: * 1. individuals who are allergic to tnf, biological products, or penicillin; 2. those who do not meet the inclusion criteria during pregnancy or lactation; 3. other situations where the researcher believes that patients are not suitable to participate in this trial.

Keywords: rmhtnf, gastric cancer, colorectal cancer, peritoneal metastasis, intraperitoneal infusion chemotherapy
natriuresis as a predictor of the haemodynamic response to steroid replacement therapy in patients in septic shock

Conditions: Septic Shock

Summary: septic shock is responsible in 20% of cases of acute adrenal insufficiency and in 50% of cases of chronic 'slow' adrenal insufficiency. given the unpredictable nature of the response to the acth stimulation test, it is recommended to systematically start steroid replacement therapy with hydrocortisone hemisuccinate (hchs) in patients in septic shock who do not respond to fluid resuscitation and who continue to suffer from haemodynamic instability despite increasing doses of noradrenaline. the interest of this corticosteroid therapy lies in its ability to reduce the duration of treatment with catecholamines, though the results are conflicting with regard to an eventual benefit for mortality. steroid replacement therapy may be deleterious. it may increase the risk of sepsis and secondary septic shock. it is also implicated in critical-illness polyneuropathy and blood glucose dysregulation. today, there is no way to identify a population of patients who respond to corticosteroid therapy. from a pathophysiological viewpoint, hchs, as well as its glucocorticoid effects, may also exert mineralocorticoid effects able to compensate for the impaired renin angiotensin aldosterone system (raas), which is responsible for the refractory aspects of septic shock. this hyperreninism-hypoaldosteronism is found with a prevalence of around 50% of cases and is defined by a plasma aldosterone/ plasma renin ratio \ 30 mmol/l. we hypothesise that natriuresis \> 30 mmol/l will make it possible to identify patients who respond to steroid replacement therapy in terms of catecholamine use.


Eligibility criteria:
inclusion criteria: * persons who have consented to take part * patients aged 18 to 85 years * admitted to an icu for a first episode of septic shock * with a dose of noradrenaline ≥ 0.25µg/kg/min * undergoing treatment with hydrocortisone hemisuccinate (hchs) exclusion criteria: * adult under guardianship * patients without national health insurance cover * pregnant or breast-feeding women * immunodepression (aids, corticosteroid treatment \> 3 weeks, organ graft, treatment with immunosuppressants) * recent intake of diuretics (\< 6 h) * long-term ace inhibitors or araii * chronic kidney failure (clearance \< 60) * cirrhosis child ≥ b * chronic heart failure (nyha iii and iv) * decision to limit or to stop treatment
the effects of age on wound healing on free gingival graft surgery in the treatment of attached keratinized gingival deficiency by determining clinical and biochemical outcomes

Conditions: Wound Healing; Tissue Grafts; Age; Vegf; TGF-β

Summary: this study aimed to assess the effects of age on wound healing on free gingival graft (fgg) surgery in the treatment of attached keratinized gingival deficiency by determining clinical and biochemical outcomes.

aim of this study was to evaluate the effect of age on clinical and biochemical healing outcomes on fgg surgery in the treatment of attached keratinized gingival deficiency (≤2 mm) at mandibular anterior region. a total of 30 systemically healthy patients, divided into two groups and planned for fgg operations, were included in this study. these groups are; group l : 15 patients in the age range of 20-35, group 2: 15 patients in the age range of 50-65. gingival crevicular fluid and wound fluid samples were taken from these patients to analyze vegf, egf and tgf-b1 levels by elisa. wound fluid samples were taken baseline, 4,7, and 14 days after surgery. clinical parameters included measurement of probing depth (pd), clinical attachment level (cal), bleeding of probing (bop), plaque index (pi), gingival index (gi) at 6 sites per tooth except the third molars were measured at baseline and l, 3 and 6 months after surgery. keratinized gingiva width, keratinized gingiva thickness of the operation sites were measured baseline and 1,3 and 6 months after surgery. vertical dimension of the graft, horizontal dimension of the graft, graft thickness were measured at baseline and 1,3,6 months after surgery. graft area measurements were calculated on standard photographs by a java-based analysis program (imagej, national institutes of health, bethesda, md) to determine the shrinkage rate of the grafts. the graft shrinkage ratio was calculated as the difference between baseline to 1-month, baseline to 3-months, baseline to 6-month graft site value. data were analyzed using appropriate statistical tests.

Eligibility criteria:
inclusion criteria: * having ≤2mm of keratinized gingiva in at least 1 mandibular anterior tooth * periodontally healthy with full-mouth bleeding and plaque score ≤ 10% * no use of any drugs that will affect periodontal tissue health and healing process * absence of any systemic condition or illness exclusion criteria: * smokers * previous periodontal surgery * a pathology in the apical region of the tooth * pregnancy, lactation
safety and efficacy of the tong-fu-xing-shen herbal formula for stroke-associated pneumonia

Conditions: Stroke; Complication

Summary: stroke-associated pneumonia (sap) is the major complication of acute intracerebral haemorrhage (aich), leads to poor clinical outcomes and increases the financial burden on the medical system. prophylactic antibiotics do not reduce the mortality rate of sap. the tong-fu-xing-shen herbal formula (tfxs) was shown to be effective for the prevention and treatment sap in a previous clinical trial. to clarify whether tfxs is effective and safe for the treatment of sap and affects the immunological mechanism of the "brain-gut-lung" pathway of sap, the investigators designed this study.

this is a multicentre, randomized, double-blind, placebo-controlled clinical trial. a total of 218 patients will be recruited and randomly assigned to the experimental group (eg) or the control group (cg) in a 1:1 ratio. the treatment course will be 10-12 consecutive days, with a 90±7-day follow-up. the primary outcome is the all-cause mortality rate and the mortality of pneumonia at the 90±7-day follow-up. secondary outcomes include changes in the gut microbiota; changes in the nihss score, bi index, mrs score, and stroke-specific quality of life scale (ss-qol) score; and so on.

Eligibility criteria:
inclusion criteria for inclusion, participants will need to fulfil all the following criteria: 1. a diagnosis of intracerebral haemorrhage according to 2019 chinese guidelines for the diagnosis and treatment of acute intracerebral haemorrhage \[9\], with a ct scan of the brain confirming acute intracerebral haemorrhage; 2. age between 18 and 85; 3. a diagnosis of sap according to the modified cdc standard \[10\]; 4. within 7 days after stroke onset; and 5. willingness to participate and to sign the informed consent form. exclusion criteria participants with any of the following conditions will be excluded: 1. cerebral haemorrhage is confirmed by examination to be caused by a brain tumour, brain trauma, blood disease, cerebrovascular malformation (a congenital abnormality) or aneurysm; 2. cerebral herniation; 3. a gcs score \<7; 4. any antibiotic treatment within 4 weeks before the start of the study; 5. pulmonary tuberculosis, pulmonary oedema, pulmonary embolism, noninfectious pulmonary oedema or respiratory circulation failure; 6. liver or kidney function parameters (such as alanine aminotransferase \[alt\], aspartate aminotransferase \[ast\] and creatinine \[cre\]) 3 times higher than the upper limit of normal; 7. a clear history of gastrointestinal diseases, such as gastrointestinal tumours and inflammatory bowel disease, or a gastrointestinal bleeding period within 3 months; 8. immune-related diseases, such as sle, rheumatoid arthritis, and sjogren's syndrome, or receiving immunotherapy for other diseases; and 9. unsuitable for the trial as decided by the researchers.

Keywords: stroke-associated pneumonia tong-fu-xing-shen herbal formula traditional chinese medicine brain-gut-lung axis randomized controlled trial
roniciclib / placebo in combination with chemotherapy in small cell lung cancer

Conditions: Small Cell Lung Carcinoma

Summary: this is a study to investigate the potential clinical benefit of roniciclib when given in combination with chemotherapy carboplatin / etoposide or cisplatin / etoposide as first line treatment in patients with extensive disease small cell lung cancer. approximately 140 patients will be randomized (1:1) to receive treatment with either roniciclib or placebo in combination with chemotherapy. roniciclib is an oral (i.e. taken by mouth) protein kinase inhibitor. a kinase inhibitor targets certain key proteins that are essential for the survival of the cancer cell. the growth of the tumor may be decreased by preventing these specific proteins from functioning. by specifically targeting these proteins, roniciclib in combination with chemotherapy may stop cancer growth. the primary endpoint (the most meaningful result to be tracked) of this study is based on the progression free survival, i.e. the time the disease is not worsening. the aim is to show that the therapy with roniciclib in combination with chemotherapy prolongs the time the disease is not worsening in this patient population compared to patients receiving placebo in combination with chemotherapy.


Eligibility criteria:
inclusion criteria: * male or female subjects aged ≥18 years (or country-specific legal age of maturity, if \>18 years) * histologically or cytologically confirmed (extensive-stage disease) ed sclc (small cell lung cancer) * at least 1 solid tumor lesion measurable by computer tomography (ct) scan or magnetic resonance imaging (mri) according to response evaluation criteria in solid tumors (recist) version 1.1 * eastern cooperative oncology group (ecog) performance status of 0 - 1 exclusion criteria: * prior systemic anticancer therapy for sclc (including previous therapy with a cyclin-dependent kinase \[cdk\] inhibitor)

Keywords: small cell lung carcinoma, first line extensive disease small cell lung cancer
study of zonal and balance acupuncture pain relief effect

Conditions: Pain Syndrome

Summary: the aim of the study is to investigate how effective is zonal acupuncture method compared to balance method to obtain a short coming pain relief effect, which takes place several minutes after needle insertion.

main purpose of the study is to estimate the efficiency of the zonal acupuncture method compared to control group and the balance acupuncture method. this study includes random completion of 3 groups of participants : zonal acupuncture, control group, balance acupuncture approximately 20 participants each. the zonal acupuncture group will receive a treatment according to a zonal method and a pain level will be estimated by the investigator according to a visual analog pain scale (vas) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. if possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded. the control group will provide only the estimation of the the pain level according to a visual analog pain scale (vas) but receive no acupuncture treatment. then if possible the pain level will be measured again approximately 24 hours after the first measurement and the change of the pain level will be recorded for a control group too. the balance acupuncture group will receive a treatment according to a balance method, and a pain level will be estimated according to a visual analog pain scale (vas) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. if possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded. these measurements are primary outcome of the experiment. provided statistically consistent they will be treated to extract method efficiency estimation. the participants from all tree groups may receive drug analgesia at some recorded moment of time before the procedure, however the investigators want to investigate the effect of acupuncture analgesia at the time when no other analgesia effect is present, so the investigators can exclude possible interference.

Eligibility criteria:
inclusion criteria: * post traumatic pain syndrome * vertebrogenic pain syndrome exclusion criteria: * oncological diseases * narcotic dependency * psychiatric disorders
safety/efficacy of bromfenac ophthalmic solution for ocular inflammation and pain associated with cataract surgery

Conditions: Pain; Inflammation

Summary: the primary objective of this study is to investigate the efficacy and safety of bromfenac ophthalmic solution for treatment of ocular inflammation and pain in subjects who undergo cataract extraction and intraocular lens implantation.


Eligibility criteria:
inclusion criteria: * scheduled for unilateral cataract surgery with no other ophthalmic surgical procedures planned during cataract surgery * agree to return for all required visits * agree to avoid disallowed medications exclusion criteria: * known hypersensitivity to bromfenac and salicylates

Keywords: cataract extraction anti-inflammatory agents, non-steroidal
a study of viekira/exviera for korean hepatitis c patients according to the standard for re-examination of new drugs

Conditions: Hepatitis C Virus (HCV)

Summary: post-marketing surveillance study to evaluate the real world safety and effectiveness of viekira/ exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) administered under a normal, routine treatment practice by korean patients with hepatitis c.


Eligibility criteria:
inclusion criteria: * participants with type c hepatitis * participants prescribed viekira/exviera in accordance with approved local label exclusion criteria: * none

Keywords: hepatitis c paritaprevir ritonavir ombitasvir dasabuvir
phase ib study of anetumab ravtansine in combination with pegylated liposomal doxorubicin in patients with recurrent mesothelin-expressing platinum-resistant cancer

Conditions: Ovarian Neoplasms

Summary: anetumab ravtansine is developed for the treatment of patients with recurrent platinum-resistant ovarian cancer. the purpose of the proposed trial is to identify the maximum tolerated dose of anetumab ravtansine that could be safely combined with pegylated liposomal doxorubicin in this indication.


Eligibility criteria:
inclusion criteria: * subjects with locally invasive or metastatic, epithelial ovarian, fallopian tube, or primary peritoneal cancer * subjects must provide samples of tumor tissue * subjects must have an eastern cooperative oncology group (ecog) performance status of 0 or 1 exclusion criteria: * subjects with low-grade ovarian, fallopian tube, or primary peritoneal cancer * women who are pregnant or breast feeding * subjects who have an active hepatitis b virus or hepatitis c virus infection requiring treatment as defined in the protocol

Keywords: mesothelin-expressing platinum-resistant cancer
pilot 3d contrast-enhanced ultrasound imaging to predict treatment response in liver metastases

Conditions: Liver Metastases; Colon Cancer

Summary: patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment. patients were selected as a possible participant in this study because they are identified as having liver metastases

primary objectives: i. the purpose of this study is to perform a pilot feasibility study on 3-dimensional (3d) ultrasound imaging of liver metastases and to evaluate whether perfusion characteristics (measurements of blood-flow) of hepatic metastases can predict tumor response to treatment in patients with liver metastases. the investigators long term goal is to assess whether early perfusion changes at 2 weeks after chemotherapy initiation can be used as a non-invasive early biomarker for treatment response assessment. outline: patients undergo 3d dynamic contrast-enhanced ultrasound imaging before initiation of chemotherapy, at 2 weeks, and at 2 months.

Eligibility criteria:
inclusion criteria * provides written informed consent and is willing to comply with protocol requirements. * has at least 1 focal lesion in liver or kidney * patient may be (i) in the process of receiving treatment (1 scan session), (ii) never treated (3 scan sessions) or (iii) changing treatment regimen/ type and/or receiving a new form of treatment and/or has been on a treatment break ('holiday')(3 scan session) * is at least18 years of age. exclusion criteria * is determined by the investigator that the subject is clinically unsuitable for the study. * known right to left cardiac shunt, bidirectional or transient. * hypersensitivity to perflutren. * hypersenstivity to the contrast agent definity. * pregnant and lactating women
mothers and others: family-based obesity prevention for infants and toddlers

Conditions: Obesity

Summary: the purpose of this study is to conduct a randomized controlled trial among 468 non-hispanic black mothers and their families to test the efficacy of mothers and others, a multi-component home visitation program, compared to an attention control (child safety) in promoting appropriate weight gain during infancy.

mothers and others: family-based obesity prevention for infants and toddlers will be one of the first to meet the unique needs of individual families by delivering anticipatory guidance on infant care, feeding and growth through multiple channels and to multiple caregivers. primary modes of delivery for the obesity prevention group (experimental arm) will include face-to-face counseling through 8 home visits (1 by a certified lactation consultant), 5 health newsletters, and approximately 160 cue-based text messages. the injury prevention group (active comparator) will receive messages on child safety delivered through similar channels. our main outcome is infant/toddler growth, captured by mean weight-for-length z-scores (wlz) at 15 months, mean change in wlz between 0-15 months, and likelihood of overweight (wlz ≥ 95th percentile) at 15 months. differences between groups are expected to be achieved through uptake of targeted health behaviors, including a greater likelihood of breastfeeding initiation, exclusivity and duration; after 6 months, higher dietary intakes of whole fruits and vegetables and lower intakes of energy-dense snack foods; age-appropriate durations of infant and toddler sleep; and, lower levels of television and electronic media exposure. we further hypothesize that these targeted health behaviors will be achieved through modifiable risk factors underpinning the intervention, namely more positive breastfeeding attitudes; higher levels of parenting and breastfeeding self-efficacy; higher levels of perceived social support; higher responsive feeding style scores; improved accuracy in perceiving infant/toddler weight status; and, diminished parental perceptions of infant fussiness.

Eligibility criteria:
inclusion criteria: * self identifies as non-hispanic, african-american * less than 28 weeks pregnant at time of screening and recruitment * expecting a singleton birth * maternal age at time of birth will be at 18-39 years * lives within specified distance of study site * not intending to leave study area before expectant child's 15th month of life * agreeable to referring another family member/caregiver to participate in the study exclusion criteria: * pre-term birth (\<= 36 weeks gestation) * less than 18 years at time of delivery * delivers infant with a congenital anomaly or medical condition that significantly affects feeding (e.g., cleft lip and/or palate, metabolic disease) * delivers multiples * newborn nursery, neonatal intensive care unit (nicu), or maternity floor stay for 7 or more days after the delivery

Keywords: infant diet family diet responsive feeding infant temperament physical activity television